



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ryuichi Morishita et al.**Application No.:** 09/869,475**Filed:** October 10, 2001**Confirmation No.:** 4309**For:** GENE THERAPY FOR DIABETIC
ISCHEMIC DISEASE**Examiner:** Brian Whiteman**Art Unit:** 1635**Attorney Reference No.:** 6235-59221-01**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV514604036US in an envelope addressed to: MAIL STOP RCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)Date Mailed July 13, 2004

MAIL STOP RCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(4)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



SAS:sas 07/13/04 6235-59221-01 Document in ProLaw

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6235-59221-01
		Application Number	09/869,475
		Filing Date	October 10, 2001
		First Named Inventor	Ryuichi Morishita
		Art Unit	1635
		Examiner Name	Brian Whiteman
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
		Kala <i>et al.</i> , "Angiogenesis und Vaskulogenes," <i>Hertz</i> 25:611-622, 2000 (English abstract)	
		Li <i>et al.</i> , "Technology evaluation: gene therapy (FGF-5), Vical," <i>Curr. Opin. Molec. Therap.</i> 1:260-5, 1999	
		Morishita <i>et al.</i> , "Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy," <i>Hypertension</i> 33:1379-1384, 1999	
		Prud'homme and Chang, "Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon gamma receptor/IgG1 fusion protein," <i>Gene Therapy</i> 6:771-7, 1999	
		Rochlitz, "Gene Therapy of Cancer," <i>Drugs of Today</i> 36:619-629, 2000	
		Udea <i>et al.</i> , "Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart," <i>Ann. Thorac. Surg.</i> 67:1726-31, 1999.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	